Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Non-interventional Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis
- First Posted Date
- 2012-03-23
- Last Posted Date
- 2016-11-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 50
- Registration Number
- NCT01562327
An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor
Completed
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2012-03-19
- Last Posted Date
- 2017-01-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1239
- Registration Number
- NCT01557348
A Single Dose Study of Tamiflu in Volunteers in Dialysis And in Volunteers With Reduced Creatinine Clearance
- First Posted Date
- 2012-03-16
- Last Posted Date
- 2016-07-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 16
- Registration Number
- NCT01556633
An Observational Study of Avastin in First Line in Elderly Patients With Metastatic Colorectal Cancer (CASSIOPEE)
Completed
- Conditions
- Colorectal Cancer
- First Posted Date
- 2012-03-15
- Last Posted Date
- 2019-03-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 402
- Registration Number
- NCT01555762
- Locations
- 🇫🇷
Hopital Victor Jousselin; Gastro Enterologie, Druex, France
🇫🇷Clinique De L Europe; Pmsi, Amiens, France
🇫🇷Centre Hospitalier de L'Agglomeration Montargeoise; Medecine Polyvalente A Orientation Mi & Cancero, Amilly, France
An Global Comparative Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis
Completed
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2012-03-05
- Last Posted Date
- 2016-02-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1225
- Registration Number
- NCT01543503
A Pharmacodynamic and Pharmacokinetic Study of RO4917838 in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy Volunteer
- Interventions
- Drug: RO4917838Drug: Placebo to RO4917838Other: Alcohol
- First Posted Date
- 2012-03-05
- Last Posted Date
- 2017-05-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 25
- Registration Number
- NCT01543529
- Locations
- 🇫🇷
BIOTRIAL, Rennes, France
An Observational Study of Tarceva (Erlotinib) in Elderly Patients With Advanced Non-Small Cell Lung Cancer
Completed
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- First Posted Date
- 2012-02-20
- Last Posted Date
- 2015-10-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 465
- Registration Number
- NCT01535729
A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With Systemic Sclerosis
Phase 3
Completed
- Conditions
- Sclerosis, Systemic
- Interventions
- Drug: PlaceboDrug: tocilizumab [RoActemra/Actemra]
- First Posted Date
- 2012-02-15
- Last Posted Date
- 2016-09-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 87
- Registration Number
- NCT01532869
A Study of Drug-Drug Interaction Between Danoprevir/Low-Dose Ritonavir and Raltegravir in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy Volunteer
- Interventions
- First Posted Date
- 2012-02-13
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 20
- Registration Number
- NCT01531647
A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers
- First Posted Date
- 2012-02-02
- Last Posted Date
- 2017-11-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 208
- Registration Number
- NCT01524978
- Locations
- 🇫🇷
Centre Georges François Leclerc, Dijon, France
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸Arizona Oncology, Tucson, Arizona, United States
© Copyright 2025. All Rights Reserved by MedPath